You have
Stage IIA
Melanoma

Introduction:

Patients with Stage IIA disease consists of two groups. 

Group 1. Patients with T2b disease (i.e., Breslow thickness between 1.0 -2.0mm and with ulceration).

Group 2. Patients with T3a disease (i.e., Breslow thickness between 2.0 -4.0mm and with no ulceration). 

Survivor Outcome:

According to the 2018 AJCC data, for patients with stage IIA disease, the 5-year and 10-year melanoma-specific survival probability are 94% and 88%, respectively.

Treatment:
Adopted from NCCN Guideline 2022

Treatment for Group 1 patients  (i.e.,T2B Disease):
For this group, the treatment involves excision of the tumor along with a standard surgical margin of 1-2 cm.

Sentinel Lymph Node Biopsy (SLNB) is discussed and offered.

Routine imaging (e.g., X-ray or CT scan) or lab tests are not recommended.

No other treatment modalities, such as immunotherapy or targeted therapy, are needed.
 

Treatment for Group 2 patients  (i.e.,T3A Disease):

For this group, the treatment involves excision of the tumor along with a standard surgical margin of >2 cm.

Sentinel Lymph Node Biopsy (SLNB) is discussed and offered.

Routine imaging (e.g., X-ray or CT scan) or lab tests are not recommended.

No other treatment modalities, such as immunotherapy or targeted therapy, are needed.

​